Xilio Development Inc

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of masked immuno-oncology therapies. Its pipeline includes XTX501, a bispecific PD-1 / masked IL-2 for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational masked IL-12 in a Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO▲

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer. Harshbarger brings over 20 years of executive leadership and legal expertise in the biopharmaceutical industry, most recently serving as chief legal officer at Astria Therapeutics until its acquisition by BioCryst Pharmaceuticals. At Xilio, he joins the leadership team as the company advances its pipeline of masked immuno-oncology therapies, including XTX501, a bispecific PD-1 and masked IL-2 candidate, and multiple masked T-cell engagers. His prior roles include interim chief executive officer and general counsel at Novelion Therapeutics and general counsel at Aegerion Pharmaceuticals.

XLO ▲

GlobeNewswire·81dRead more →